SCHEMBL16099677

SCHEMBL16099677

CC(C)(C)OC(=O)Cn1cc(CC(N)C(=O)O)c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.58
▸ MAPT P10636 2/20 0.58
▸ RECQL P46063 1/20 0.58
▸ GAA P10253 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ SCN9A Q15858 1/20 0.43
▸ SLC7A5 Q01650 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MPO P05164 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7434865 1.00 ALDH1A1 (0.58) ALDH1A1MAPTRECQLGAAKMT2A
SCHEMBL16099676 1.00 ALDH1A1 (0.58) ALDH1A1MAPTRECQLGAAKMT2A
SCHEMBL30002479 1.00 ALDH1A1 (0.58) ALDH1A1MAPTRECQLGAAKMT2A
SCHEMBL30343690 1.00 ALDH1A1 (0.58) ALDH1A1MAPTRECQLGAAKMT2A
SCHEMBL19456372 0.84 ALDH1A1 (0.41) ALDH1A1MAPTRECQLGAAKMT2A
SCHEMBL30711166 0.84 PLA2G2A (0.48) ALDH1A1MAPTRECQLSCN9ASLC7A5
SCHEMBL19410203 0.84 PLA2G2A (0.48) ALDH1A1MAPTRECQLSCN9ASLC7A5
SCHEMBL19410201 0.84 PLA2G2A (0.48) ALDH1A1MAPTRECQLSCN9ASLC7A5
SCHEMBL16100108 0.84 CTSS (0.48) GAAPOLBSCN9AHDAC10HDAC6
SCHEMBL31407630 0.84 CTSS (0.48) GAAPOLBSCN9AHDAC10HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2026-03-12 — — US disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 — — US disclosed
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2025-05-22 — — US disclosed
EP-4526323-A1 MACROCYCLIC IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2025-03-26 — — EP disclosed
EP-4499667-A1 MACROCYCLIC IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2025-02-05 — — EP disclosed
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-12 — — US disclosed
US-20240360178-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 — — US disclosed
EP-4441069-A1 MACROCYCLIC IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2024-10-09 — — EP disclosed
US-20240199701-A1 IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-06-20 — — US disclosed
CN-118159549-A Immunomodulators 百时美施贵宝公司 2024-06-07 — — CN disclosed
US-20170260237-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-14 — — US disclosed
EP-3191113-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS Bristol-Myers Squibb Company (US) 2017-07-19 — — EP disclosed
US-20160340391-A1 Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions BRISTOL MYERS SQUIBB CO (US) 2016-11-24 — — US disclosed
US-20160158349-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS BRISTOL MYERS SQUIBB CO (US) 2016-06-09 — — US disclosed
US-9308236-B2 Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-12 — — US disclosed
WO-2016039749-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-17 — — WO disclosed
EP-2970390-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS Bristol-Myers Squibb Company (US) 2016-01-20 — — EP disclosed
CN-105209479-A Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions BRISTOL MYERS SQUIBB CO 2015-12-30 — — CN disclosed
US-20140294898-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS BRISTOL-MYERS SQUIBB COMPANY 2014-10-02 — — US disclosed
WO-2014151634-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199701-A1 IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 ALDH1A1 3723/4885MAPT 3711/4885RECQL 2360/4885
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 ALDH1A1 2172/4885MAPT 4152/4885RECQL 1310/4885
US-20140294898-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS CD274, PDCD1, PDCD1LG2 ALDH1A1 3138/4885MAPT 2856/4885RECQL 2704/4885
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 ALDH1A1 476/4885MAPT 4639/4885RECQL 2863/4885
US-20170260237-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS CD274, PDCD1, PDCD1LG2 ALDH1A1 3138/4885MAPT 2856/4885RECQL 2704/4885
US-20240360178-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 ALDH1A1 1254/4885MAPT 4066/4885RECQL 1684/4885
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 ALDH1A1 1290/4885MAPT 4015/4885RECQL 1765/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 ALDH1A1 1254/4885MAPT 4066/4885RECQL 1684/4885
US-20160340391-A1 Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions CD274, PDCD1, PDCD1LG2 ALDH1A1 3138/4885MAPT 2856/4885RECQL 2704/4885
US-20160158349-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS CD274, PDCD1, PDCD1LG2 ALDH1A1 3138/4885MAPT 2856/4885RECQL 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback